Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom
Clinical Pharmacology & Therapeutics · 2023-06 · 113 (6) · 1315-1325
DOI: 10.1002/cpt.2891 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 28.03.2023. Verfasst von Rakshit S Tanna und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA. Hauptthemen laut MEDLINE: Mitragyna, Biological Products. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCCIH NIH HHS.
Abstract (Originalsprache)
Oral formulations prepared from the leaves of the kratom ( Mitragyna speciosa ) plant are increasingly used for their opioid‐like effects to self‐manage opioid withdrawal and pain. Calls to US poison centers involving kratom exposures increased >50‐fold from 2011–2017, one‐third of which reported concomitant use of kratom with drugs of abuse. Many of these drugs are eliminated primarily via cytochrome P450 (CYP) 3A and CYP2D6, raising concerns for potential adverse pharmacokinetic kratom‐drug interactions. The impact of a single low dose of kratom tea (2 g) on the pharmacokinetics of the CYP3A probe midazolam (2.5 mg) and CYP2D6 probe dextromethorphan (30 mg) were assessed in 12 healthy adult participants after oral administration. Kratom showed no effect on dextromethorphan area under the plasma concentration time‐curve (AUC) and maximum concentration ( C max ; geometric mean ratio (90% confidence interval) 0.99 (0.83–1.19) and 0.96 (0.78–1.19), respectively) but a modest increase in midazolam AUC and C max (1.39 (1.23–1.57) and 1.50 (1.32–1.70), respectively). Lack of change in midazolam half‐life (1.07 (0.98–1.17)) suggested that kratom primarily inhibited intestinal CYP3A. This inference was further supported by a physiologically based pharmacokinetic drug interaction model using the abundant alkaloid mitragynine, a relatively potent CYP3A time‐dependent inhibitor in vitro ( K I , ~4 μM; k inact , ~0.07 min −1 ). This work is the first to clinically evaluate the pharmacokinetic drug interaction potential of kratom. Co‐consuming kratom with certain drugs extensively metabolized by CYP3A may precipitate serious interactions. These data fill critical knowledge gaps about the safe use of this increasingly popular natural product, thereby addressing ongoing public health concerns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA.
- Center of Excellence for Natural Product Drug Interaction Research, Spokane, Washington, USA.
- Elson S. Floyd College of Medicine, Washington State University, Spokane, Washington, USA.
- Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA.
- Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina, USA.
- Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, Washington, USA.
ORCID-Profile: James T Nguyen, Nicholas H Oberlies, Mary F Paine
Förderung
- NCCIH NIH HHS
Zitieren
APA
Tanna, R. S., Nguyen, J. T., Hadi, D. L., Layton, M. E., White, J. R., Cech, N. B., Oberlies, N. H., Rettie, A. E., Thummel, K. E., & Paine, M. F. (2023). Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom. Clinical Pharmacology & Therapeutics, 113(6), 1315-1325. https://doi.org/10.1002/cpt.2891
Vancouver
Tanna RS, Nguyen JT, Hadi DL, Layton ME, White JR, Cech NB, et al. Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom. Clinical Pharmacology & Therapeutics. 2023;113(6):1315-1325. doi:10.1002/cpt.2891
BibTeX
@article{Tanna2023,
author = {Tanna, Rakshit S and Nguyen, James T and Hadi, Deena L and Layton, Matthew E and White, John R and Cech, Nadja B and Oberlies, Nicholas H and Rettie, Allan E and Thummel, Kenneth E and Paine, Mary F},
title = {Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom},
journal = {Clinical Pharmacology & Therapeutics},
year = {2023},
volume = {113},
number = {6},
pages = {1315--1325},
doi = {10.1002/cpt.2891}
}
EUVIMED